Investors bumped its shares higher following a decent, if unspectacular, earnings report.Investors happily greeted the latest news from Abbott Laboratories (ABT 1.52%) on Hump Day. After the storied healthcare company unveiled its third-quarter results, those folks traded its stock up by 1.5%. That was good enough to edge past the S&P 500 index's 0.5% gain.A pair of modest beatsFor the quarter, Abbott's revenue totaled just under $10.64 billion, for year-over-year growth of almost 5%. Non-GAAP (adjusted) ne ...

Abbott Laboratories (ABT) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.21, which beat the Zacks Consensus Estimate by 0.8%. The figure also improved 6.1% from the prior-year quarter’s level.GAAP EPS came in at 94 cents, up 14.6% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, ABT stock edged up 0.03% during the pre-market trading today.ABT’s Q3 RevenuesWorldwide sales of $10.64 billion were up 4.9% year over ye ...

Abbott Laboratories (NYSE:ABT) Q3 2024 Results Conference Call October 16, 2024 9:00 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Phil Boudreau - Executive Vice President, Finance and Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan David Roman - Goldman Sachs Joshua Jennings - TD Cowen Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Ma ...

Key TakeawaysAbbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices.Sales were also higher at its pharmaceutical unit, but fell at its diagnostics and nutrition divisions.Abbott boosted the midpoint of its full-year earnings forecast. Abbott Laboratories (ABT) shares rose Wednesday, after the drug and healthcare products maker reported better-than-expected quarterly results and raised the midpoint of its profit outlook on strong demand for its medical devi ...

This morning, we see a new print on international trade as well as further articulation on Q3 earnings, particularly in banking/finance and Big Pharma. Pre-market futures are slightly up at this hour: the Dow +22 points, the S&P 500 +1 and the Nasdaq +5 points. Both the Dow and S&P made all-time closing highs Monday afternoon.Import Prices Mixed in SeptemberThe latest headline on Import Prices for last month came in this morning at -0.4%. This is 10 basis points (bps) below expectations, which is also where ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any in ...

For the quarter ended September 2024, Abbott (ABT) reported revenue of $10.64 billion, up 4.9% over the same period last year. EPS came in at $1.21, compared to $1.14 in the year-ago quarter.The reported revenue represents a surprise of +0.71% over the Zacks Consensus Estimate of $10.56 billion. With the consensus EPS estimate being $1.20, the EPS surprise was +0.83%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their n ...

Abbott (ABT) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.83%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $1.10 per share when it actually produced earnings of $1.14, delivering a surprise of 3.64%.Over the l ...

Abbott Laboratories TodayABTAbbott Laboratories$115.50 -0.55 (-0.47%) 52-Week Range$91.25▼$121.64Dividend Yield1.90%P/E Ratio36.44Price Target$125.54Add to WatchlistThere are many reasons to own Abbott Laboratories NYSE: ABT, but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the 11th top-returning stock since 1937 and #1 among healthcare names. The critical takeaways from ...

Exhibit 99.1 1 News Release Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range – Sales of $10.6 billion driven by strong underlying base business performance – Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent , led by double-digit growth in Medical Devices – Continues to strengthen portfolio with steady cadence of new product approvals, reimbursement coverage, and clinical data 1 ABBOTT PARK, Ill., Oct. 16, 2024 ...